Key Points {#FPar1}
==========

Co-Crystal of Tramadol--Celecoxib (CTC), a first-in-class active pharmaceutical ingredient (API--API) co-crystal of rac-tramadol·HCl and celecoxib, is in development for the treatment of moderate to severe acute pain.Food effects are reported for standard drug formulations of celecoxib; the present study investigated the effects of food on the oral bioavailability of tramadol and celecoxib after CTC (200 mg) administration.As for standard drug formulations of the individual reference products, food increased the bioavailability of celecoxib but not that of tramadol; therefore, as for these reference products, specific dosing recommendations relating to meal times are not anticipated to be required for CTC.

Introduction {#Sec1}
============

Pharmaceutical co-crystals, which usually consist of an active pharmaceutical ingredient (API) and one or more co-formers, provide a means to modify the physicochemical, pharmacokinetic---and therefore potentially the clinical---properties of the constituent API \[[@CR1]--[@CR3]\]. Co-crystals containing more than one API (multidrug or 'API--API' co-crystals) may also provide a novel method of delivering a drug treatment with multiple mechanisms of action. Co-Crystal of Tramadol--Celecoxib (CTC) is a first-in-class API--API co-crystal in development for the treatment of moderate to severe acute pain.

CTC contains rac-tramadol·hydrochloride (HCl) and celecoxib in a 1:1 molecular ratio, with 100 mg CTC comprising 44 mg tramadol.HCl and 56 mg celecoxib. This co-crystal targets pain through four complementary mechanisms of action: cyclooxygenase-2 inhibition, µ-opioid receptor agonism, noradrenaline reuptake inhibition and serotonin reuptake inhibition \[[@CR4]\]. CTC may therefore provide multimodal analgesia, a treatment approach recommended in acute pain \[[@CR5], [@CR6]\], the optimal management of which continues to be hampered by lack of treatment efficacy \[[@CR5], [@CR7]\] and issues regarding side effects \[[@CR8]\]. Analytical studies have confirmed that the physicochemical properties of both tramadol and celecoxib are modified by co-crystallisation \[[@CR4]\]. For example, the intrinsic dissolution rate of tramadol is slower, and that of celecoxib faster, compared with individual reference products \[[@CR4]\]. Synergistic antinociceptive effects have been observed in preclinical in vivo studies, without potentiation of adverse effects \[[@CR9]\]. The analgesic effects of CTC (100, 150 and 200 mg) have also been demonstrated in a Phase 2 clinical study in patients with acute moderate to severe pain following extraction of two or more impacted third molars requiring bone removal \[[@CR10]\].

The clinical pharmacokinetics of CTC were first characterised in two Phase 1 studies conducted in healthy male and female subjects; one assessing a single dose of CTC \[[@CR11]\] and one assessing multiple doses \[[@CR12]\]. In both studies, differences in the pharmacokinetics of tramadol and celecoxib were seen after administration of CTC compared with after administration of the individual reference products (immediate-release tramadol or celecoxib) alone or in free combination. In the case of tramadol, a lower maximum observed plasma concentration (*C*~max~), slightly prolonged time to *C*~max~ (*T*~max~) and similar area under the plasma concentration--time curve (AUC) were observed with CTC. In the case of celecoxib pharmacokinetics after CTC administration, celecoxib had a lower *C*~max~ compared with celecoxib alone, and a faster *T*~max~ compared with celecoxib alone or in free combination with tramadol \[[@CR11], [@CR12]\].

The Phase 1 studies described above were conducted in fasting conditions. The bioavailability of tramadol from its standard drug formulation is not affected by food intake \[[@CR13]\]. However, a high-fat meal slows absorption of celecoxib from its standard formulation by around 1 h, and increases the *C*~max~ and AUC \[[@CR14], [@CR15]\]. The primary objective of the present study was therefore to assess the bioavailability of tramadol and celecoxib after a single dose of CTC, when administered in the fed or fasting state. The secondary objective was to evaluate the safety of CTC following single-dose administration in the fed or fasting state.

Methods {#Sec2}
=======

Study Subjects {#Sec3}
--------------

Subjects were male or female volunteers aged 18--55 years, with a body mass index ≥ 18.5 and \< 29 kg/m^2^. Subjects were required to be in good health, with no clinically significant findings as determined by physical examination, electrocardiogram (ECG), clinical laboratory evaluations (haematology, biochemistry and urinalysis) and review of the subject's medical history. Subjects were also required to be non-smokers (or ex-smokers for at least 6 months). Key exclusion criteria included pregnancy or lactation; a history of significant hypersensitivity to tramadol, celecoxib, sulphonamides, opioid analgesics or any related products; or a history of severe hypersensitivity reactions to any drugs. Full inclusion and exclusion criteria are included in Online Resource 1.

Study Design and Treatments {#Sec4}
---------------------------

This study was a single-centre, randomised, single-dose, open-label, two-period, two-sequence, crossover, food effect study. The study was conducted by a clinical research organisation (CRO; Algorithme Pharma) at a single site in Quebec, Canada and registered with the Therapeutic Products Directorate of Health Canada (152052). The study protocol was approved by an independent ethics committee and the study was performed in compliance with Good Clinical Practice. Institutional review board guidelines on the treatment of human subjects were followed, meeting the requirements of the Declaration of Helsinki. All subjects voluntarily enrolled in the study and gave written informed consent.

Each subject received a single oral dose of 200 mg CTC, once under fed conditions and once under fasting conditions. This dose had previously been evaluated in two earlier Phase 1 studies \[[@CR11], [@CR12]\] and was also efficacious and well tolerated in a Phase 2 study in which doses of 50, 100, 150 and 200 mg CTC were administered \[[@CR10]\]. CTC (Esteve Pharmaceuticals, S.A., Spain) was provided as two 100 mg tablets, each containing 44 mg tramadol·HCl and 56 mg celecoxib. Subjects were randomly assigned to one of two sequences---fed--fasting or fasting--fed---via a list generated using a computer application developed by Algorithme Pharma. Dosing was separated by a 7-day washout period (Fig. [1](#Fig1){ref-type="fig"}). All subjects underwent a supervised overnight fast (≥ 10 h) before each CTC administration and fasted for at least 4 h following administration, after which a standardised meal was served. In the fed condition, the overnight fast was followed by consumption of a standardised high-fat, high-calorie meal \[in line with the US Food and Drug Administration (FDA) recommendations\] \[[@CR16]\] 30 min before CTC administration. During the study, restrictions were applied to prescription medications; over-the-counter products; alcohol; xanthine, grapefruit- and pomelo-containing food or beverages; and strenuous activity. Water was permitted ad libitum until 1-h pre-CTC administration and again from 1-h post-administration. CTC was administered with approximately 240 mL water.Fig. 1Study design and subject disposition. \*The terminal phases of celecoxib could not be adequately estimated following CTC administration in the fasting state in three subjects. *AUC*~*∞*~ extrapolated area under the plasma concentration--time curve to infinity, *CTC* Co-Crystal of Tramadol-Celecoxib, *PK* pharmacokinetic, *T*~*1/2el*~ elimination half-life

Pharmacokinetic Sampling and Analytical Methods {#Sec5}
-----------------------------------------------

During each treatment period, blood samples (4 mL each) were collected for pharmacokinetic analysis before CTC administration (at 0 h) and at 0.5, 1, 1.5, 1.75, 2, 2.33, 2.67, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-administration. Additional samples were taken at 3.33, 3.67, 4.5 and 5.5 h post-administration in the fed state and at 0.75 and 1.25 h post-administration in the fasting state. Samples were collected in pre-cooled K~2~-EDTA-containing tubes and centrifuged (at 4 °C and 1500×*g* for 10 min) as soon as possible after collection. Plasma was then separated, frozen at a nominal temperature of--20 °C and transported on dry ice to the laboratory for assay.

Bioanalytical Assay {#Sec6}
-------------------

Plasma concentrations of tramadol, *O*-desmethyltramadol (tramadol's main metabolite) and celecoxib were measured using validated high-performance liquid chromatography with tandem mass spectrometry methods.

Samples (0.05 mL) were extracted by solid-phase extraction in Oasis MCX 96-well plates (10 mg sorbent, 30 μm particle size; Waters Corporation). After clean-up, the eluate obtained with methanol was used for analysis of celecoxib and the posterior eluate obtained with 5% NH~4~OH in methanol was used for analysis of tramadol and *O*-desmethyltramadol. Celecoxib was separated on an XBridge C18 column (3.5 μm 50 × 2.1 mm; Waters Corporation) and tramadol and *O*-desmethyltramadol were separated on an Acquity UPLC BEH Shield RP18 column (1.7 μm 2.1 × 50 mm; Waters Corporation) using different gradients of methanol and 0.1% formic acid in water. Detection for celecoxib was performed via tandem mass spectrometry on an API 4000 triple quadrupole mass spectrometer (Sciex, Ontario, Canada) using negative electrospray ionisation. For tramadol and *O*-desmethyltramadol, a Xevo TQ MS triple quadrupole mass spectrometer using positive electrospray ionisation (Waters Corporation) was used. Propranolol and E-6087, a cyclooxygenase-2 inhibitor, were used as internal standards for tramadol (and *O*-desmethyltramadol) and celecoxib, respectively.

During validation of these methods, parameters evaluated were linearity and range; selectivity; specificity; intra- and inter-run precision and accuracy; limit of quantification; dilution integrity; carry over; recovery; matrix effect; and stability in the autosampler at room temperature, after freeze-thaw cycles and over the long term. The lower and upper limits of quantification were 4.00 and 640.00, 1.00 and 160.00, and 2.50 and 1000.00 ng/mL, for tramadol, *O*-desmethyltramadol and celecoxib, respectively. Assay inter-run precision (coefficient of variation; CV) and accuracy (nominal values) for the limit of quantification were 8.3 and 102.5%, respectively for tramadol, 10.1 and 105.2% for *O*-desmethyltramadol and 10.5 and 107.8% for celecoxib. Assay specificity was assessed using six independent matrix sources, verified for the absence of interference, and compared with the respective limits of quantification at the retention times and mass transitions of analytes and internal standards. The absolute recovery ranged from 70.2 to 73.3% for tramadol, 76.3--80.5% for *O*-desmethyltramadol and 81.6--86.2% for celecoxib. Samples were stored for a maximum of 63 days (the long-term stability of frozen samples was confirmed up to 154 days).

Safety Assessments {#Sec7}
------------------

Safety was monitored throughout the study via the assessment of adverse events (AEs), classified using the Medical Dictionary for Regulatory Activities (MedDRA), version 13.1. Assessment of vital signs and standard clinical laboratory parameters (haematology, biochemistry and urinalysis), ECGs and a physical examination were conducted at screening and at the end of the study, and vital signs were also measured prior to each CTC administration.

Data Analyses and Statistics {#Sec8}
----------------------------

Findings from previous studies conducted with celecoxib at the CRO suggested that the intra-subject CV following a single dose of celecoxib was approximately 28% for *C*~max~ and around 12% for cumulative AUC from time zero to time of last observed quantifiable plasma concentration (AUC~*t*~). Ratios of geometric least-squares (LS) means were expected to fall between 95 and 105%. Therefore, it was estimated that 32 subjects would be required to provide an adequate assessment of the effect of food on celecoxib bioavailability following CTC administration. Thirty-six subjects were recruited to allow for the possibility of drop-outs and variations around the estimated intra-subject CV. As celecoxib was known to be subject to higher intra-subject variability than tramadol or *O*-desmethyltramadol, these calculations also provided an adequate estimation of the sample size required to assess the bioavailability of these latter two analytes.

The main pharmacokinetic parameters evaluated for all three analytes were *C*~max~; *T*~max~; AUC~*t*~; extrapolated AUC to infinity (AUC~∞~); and elimination half-life (*T*~½el~). Descriptive pharmacokinetic analyses were conducted using a non-compartmental approach and a log-linear terminal phase was assumed. The trapezoidal rule was used for AUC estimates and the terminal phase was estimated by maximizing the coefficient of determination calculated using a log-linear regression model. The natural logarithmic (ln) transformations of *C*~max~, AUC~*t*~ and AUC~∞~ were used for statistical pharmacokinetic analyses. All pharmacokinetic parameters except *T*~max~ were analysed using an analysis of variance (ANOVA; in line with regulatory requirements \[[@CR17]\]), with fixed factors of subject (nested within sequence), treatment, treatment period and sequence. *T*~max~ was analysed via a non-parametric approach, using Wilcoxon's rank sum test (Mann--Whitney *U* test). The comparative bioavailability of tramadol, M1 and celecoxib between fed and fasting states was assessed using a confidence interval (CI) approach. Fed-to-fasting ratios of geometric LS means and corresponding 90% CIs were calculated for *C*~max~, AUC~*t*~ and AUC~∞~. For each analyte, bioavailability was considered comparable if fed-to-fasting ratios and corresponding 90% CIs of these parameters were within the pre-defined range of 80--125%.

Subjects who provided measurable data in both treatment conditions were included in the descriptive and statistical pharmacokinetic analyses. All subjects who received at least one dose of CTC were included in the safety analyses.

Results {#Sec9}
=======

Subjects {#Sec10}
--------

The study was initiated on 25 January 2012 and completed on 8 February 2012. Thirty-six subjects (18 male and 18 female) were enrolled and received at least one dose of CTC; 35 of these subjects were administered single-dose CTC in both fed and fasting conditions. Subject demographics and characteristics are summarised in Table [1](#Tab1){ref-type="table"}. Thirty-four subjects (94%) were white; mean age was 35 years. One subject withdrew consent prior to dosing in the fasting state for personal reasons that were unrelated to any clinical event. Two subjects were withdrawn after dosing in the fed state due to emesis that could have affected pharmacokinetic findings. All subjects were included in the safety analysis. Thirty-three subjects provided evaluable pharmacokinetic data in both fed and fasting conditions and were therefore included in both descriptive and statistical pharmacokinetic analyses (Fig. [1](#Fig1){ref-type="fig"}). In a further three subjects, the terminal phases of celecoxib could not be adequately estimated following administration of CTC in the fasting state. Therefore, celecoxib AUC~∞~ and *T*~½el~ were not calculated for these subjects and only 30 subjects were included in the statistical analysis of these parameters for celecoxib (Fig. [1](#Fig1){ref-type="fig"}). A further subject had a measurable pre-dose *O*-desmethyltramadol concentration before the first treatment period, despite confirming that he/she had abided by protocol instructions on study drug intake. However, the pre-dose *O*-desmethyltramadol concentration was less than 5% of the *C*~max~ value in the first treatment period for this subject and was therefore considered unlikely to influence bioequivalence assessment. This subject was therefore included in the pharmacokinetic analyses.Table 1Subject demographics and other characteristics (*N *= 36)CharacteristicValueAge, years; mean (range)35 (18--54)Gender; *n* (%) Male18 (50.0) Female18 (50.0)Race; *n* (%) White34 (94.4) Asian2 (5.6)Weight, kg; mean (SD)65.7 (10.9)Height, cm; mean (SD)167.3 (10.5)Body mass index, kg/m^2^; mean (SD)23.4 (2.5)*SD* standard deviation

Pharmacokinetics {#Sec11}
----------------

Mean tramadol plasma concentration--time profiles were similar in fed and fasting conditions (Fig. [2](#Fig2){ref-type="fig"}a). Pharmacokinetic parameters for tramadol are summarised in Table [2](#Tab2){ref-type="table"}. *T*~max~ and *T*~½el~ parameters were significantly different (*p* value \< 0.05) between fed and fasting states. For *C*~max~, although statistically significant differences were found, geometric LS mean fed-to-fasting ratios and their 90% CIs were within the 80--125% range, indicating the absence of a food effect for this parameter. In the case of AUC values, no statistically significant differences were found, and the geometric LS mean fed-to-fasting ratios and their 90% CIs were within the 80--125% range, indicating the absence of a food effect (Table [3](#Tab3){ref-type="table"}).Fig. 2Mean plasma concentration versus time profiles for tramadol (**a**); *O*-desmethyltramadol (**b**); and celecoxib (**c**) following a single dose of CTC administered under fed or fasting conditions (*n* = 33). Data are means ± standard deviation. *CTC* Co-Crystal of Tramadol--Celecoxib Table 2Summary of PK parameters of tramadol, *O*-desmethyltramadol and celecoxib following a single dose of CTC administered under fed or fasting conditionsParameterFed\
*n* = 33Fasting\
*n* = 33MeanSDMeanSDTramadol *C*~max~ (ng/mL)\*267.0257.4243.6157.0 *T*~max~ (h)^a,^\*3.671.75--5.50 (range)2.671.50--6.00 (range) AUC~t~ (ng·h/mL)2719.70911.12773.15942.9 AUC~∞~ (ng·h/mL)2801.47907.72857.37948.6 *T*~½el~ (h)\*6.111.526.581.5*O*-desmethyltramadol *C*~max~ (ng/mL)56.2617.653.14319.3 *T*~max~ (h)^a^4.502.33--6.00 (range)4.002.33--8.00 (range) AUC~*t*~ (ng·h/mL)\*763.50210.7802.77230.4 AUC~∞~ (ng·h/mL)\*781.47209.4825.04231.8 *T*~½el~ (h)\*6.741.57.381.5Celecoxib *C*~max~ (ng/mL)\*525.57182.4410.31171.1 *T*~max~ (h)^a,^\*3.671.00--6.00 (range)1.250.75--6.00 (range) AUC~*t*~ (ng·h/mL)\*4411.112576.13450.352508.4 AUC~∞~ (ng·h/mL)^b,^\*4514.433002.13615.202921.1 *T*~½el~ (h)^b,^\*8.223.011.304.4*ANOVA* analysis of variance, *AUC*~*t*~ cumulative area under the concentration--time curve from time zero to time of last observed quantifiable plasma concentration, *AUC*~*∞*~ extrapolated area under the concentration--time curve to infinity, *C*~*max*~ maximum plasma concentration, *CTC* Co-Crystal of Tramadol-Celecoxib, *PK* pharmacokinetic, *SD* standard deviation, *T*~*½el*~ elimination half-life, *T*~*max*~ time to maximum plasma concentration\*A statistically significant difference between fed and fasting state \[*p* \< 0.05; ANOVA model, with fixed factors of subject effect (nested within sequence), the treatment received, the period at which it was received and the sequence in which each treatment was received\]^a^Data are median (range)^b^*n* = 30 for celecoxib AUC~∞~ and *T*~½el~ Table 3Comparative bioavailability of tramadol, *O*-desmethyltramadol and celecoxib following a single dose of CTC administered under fed or fasting conditionsParameterGeometric LS means (*n* = 33)Ratio (%)90% CIsFedFastingTramadol *C*~max~ (ng/mL)261.05236.40110.43105.34--115.76 AUC~*t*~ (ng·h/mL)2570.812616.3398.2694.48--102.20 AUC~∞~ (ng·h/mL)2660.362704.3598.3794.85--102.02*O*-desmethyltramadol *C*~max~ (ng/mL)53.2749.66107.29101.60--113.30 AUC~*t*~ (ng·h/mL)733.18768.4195.4192.40--98.53 AUC~∞~ (ng·h/mL)752.37791.2795.0892.08--98.19Celecoxib *C*~max~ (ng/mL)499.47381.54130.91116.98--146.49 AUC~*t*~ (ng·h/mL)4037.173065.13131.71124.54--139.30 AUC~∞~ (ng·h/mL)^a^4087.733160.35129.34121.78--137.38*AUC*~*t*~ cumulative area under the concentration--time curve from time zero to time of last observed quantifiable plasma concentration, *AUC*~*∞*~ extrapolated area under the concentration--time curve to infinity, *CI* confidence interval, *C*~*max*~ maximum plasma concentration, *CTC* Co-Crystal of Tramadol-Celecoxib, *LS* least-squares^a^*n* = 30 for celecoxib AUC~∞~

Mean plasma concentration--time curves for *O*-desmethyltramadol were also similar in fed and fasting conditions (Fig. [2](#Fig2){ref-type="fig"}b). *O*-desmethyltramadol *C*~max~, *T*~max~, AUC and *T*~½el~ values are shown in Table [2](#Tab2){ref-type="table"}. There was no statistically significant difference in *C*~max~ between fed and fasting conditions. Although *O*-desmethyltramadol AUC and *T*~½el~ values had a *p* value \< 0.05 between fed and fasting states, the geometric LS mean fed-to-fasting ratios and corresponding 90% CIs were between 80 and 125% for *C*~max~ and for AUC values, indicating the absence of a food effect for *O*-desmethyltramadol (Table [3](#Tab3){ref-type="table"}).

The pharmacokinetics of celecoxib were subject to a food effect (Fig. [2](#Fig2){ref-type="fig"}c). All celecoxib pharmacokinetic parameters (Table [2](#Tab2){ref-type="table"}) showed a significant difference (*p* value \< 0.05) between the fed and fasting states. *T*~max~ was significantly delayed under fed versus fasting conditions (median value of 3.67 and 1.25 h, respectively). The half-life of celecoxib was shorter in the fed state than in the fasting state (8.22 and 11.30 h). Fed-to-fasting geometric LS mean ratios and corresponding 90% CIs for *C*~max~, \[130.91% (116.98--146.49)\], AUC~*t*~ \[131.71% (124.54--139.30)\] and AUC~∞~ \[129.34% (121.78--137.38)\] were outside the 80 and 125% range for comparative bioavailability, indicating a food effect on celecoxib pharmacokinetics (Table [3](#Tab3){ref-type="table"}).

Safety {#Sec12}
------

There were no serious AEs or deaths and no subject was withdrawn from the study for safety reasons. Twenty-three subjects (23/36; 63.9%) experienced a total of 88 AEs. After administration of CTC in fed conditions, 17 subjects (17/36; 47.2%) reported 46 AEs, of which 43 were assessed as possibly related to study drug. After receipt of CTC in fasting conditions, 20 subjects (20/35; 57.1%) reported 42 AEs, of which 40 were assessed as possibly related to study drug. Dizziness \[reported in 7/36 (19.4%) and 9/35 (25.7%) of subjects in fed and fasting states, respectively\], somnolence \[8 (22.2%) and 4 (11.4%)\] and nausea \[5 (13.9%) and 5 (14.3%)\] were the most commonly reported AEs (Table [4](#Tab4){ref-type="table"}). AEs ranged from mild to severe. Four severe AEs were recorded after treatment in the fed state \[nausea (*n* = 2) and vomiting (*n* = 2)\] and two after treatment in the fasting state \[dizziness (*n* = 1) and vomiting (*n* = 1); Table [4](#Tab4){ref-type="table"}\]. Two subjects required rescue medication for headache following the first administration of CTC. Two subjects had clinically significant urinalysis laboratory values after the study (one subject was positive for white blood cells and one for red blood cells). Both were lost to follow-up before end-of-study. No clinically significant effects on vital signs, ECGs or physical examination were noted during the study.Table 4Summary of adverse eventsFed\
*n* = 36Fasting\
*n* = 35Subjects with at least one AE, *n* (%)17 (47.2)20 (57.1)Number of AEs4642*Most commonly reported AEs occurring in at least two subjects (Number of subjects/number of AEs)*Nervous system disorders Dizziness7/79/11 Somnolence8/94/4 Headache3/43/3 Hypoaesthesia1/51/1Gastrointestinal disorders Nausea5/55/6 Vomiting2/72/3General disorders and administration site conditions Fatigue0/02/2 Pallor1/11/1Injury, poisoning and procedural complications Vessel puncture site reaction2/20/0*Severe AEs (Number of subjects/number of severe AEs)*Gastrointestinal disorders Nausea2/20/0 Vomiting2/21/1Nervous system disorders Dizziness0/01/1Each subject was counted only once per drug administration within each system organ class and MedDRA preferred AE term*AE* adverse event, *MedDRA* medical dictionary for regulatory activities

Discussion {#Sec13}
==========

In this randomised crossover study of healthy male and female subjects, the bioavailability of tramadol after a single dose of CTC, as determined by bioequivalence analyses, was unaffected by food, whereas that of celecoxib was increased after consumption of a high-fat meal. Absorption of celecoxib was also slowed in the fed state compared with the fasting state. The single-dose safety profile of CTC was similar following administration in the fed or fasting state and CTC was well tolerated under both conditions.

The primary results from the current study, namely that food had no effect on tramadol bioavailability but increased celecoxib bioavailability, are consistent with those observed when the standard drug formulations of tramadol and celecoxib are administered individually. Food intake does not affect the bioavailability of standard-formulation tramadol \[[@CR13]\]. However, for standard-formulation celecoxib, high-fat meals are known to increase celecoxib *C*~max~ by approximately 40--60% and AUC by 10--20%, and delay absorption by approximately 1--2 h, compared with fasting conditions \[[@CR14], [@CR15]\]. In vitro studies have suggested that this effect of food on celecoxib bioavailability may be linked to an increase in bile secretion \[[@CR18]\].

In line with regulatory requirements \[[@CR16], [@CR17]\], this Phase 1 food effect study was conducted using a randomized, two-period, two-sequence, single-dose, crossover design, in healthy volunteers. While such a design has some inherent limitations, we do not believe that these negatively impact on data interpretation. For example, the European Medicines Agency recommends single-dose studies for their superior sensitivity in detecting differences in *C*~max~ when compared to the same design using multiple doses. In addition, regulatory authorities suggest that bioequivalence studies be conducted in healthy volunteers where possible, and that this permits extrapolation to other populations \[[@CR16], [@CR17]\].

The data reported herein are supported by findings from other CTC clinical trials. The fasting pharmacokinetic data obtained in the present study are similar to those collected in earlier Phase 1 studies of CTC, in which dosing was carried out under fasting conditions \[[@CR11], [@CR12]\]. In the present study, median *T*~max~ values of celecoxib and tramadol after CTC dosing under fasting conditions were 1.25 and 2.67 h, respectively. In an earlier single-dose Phase 1 CTC study, corresponding median *T*~max~ values after CTC dosing under fasting conditions were 1.50 and 2.67 h for celecoxib and tramadol, respectively. These values were slightly higher in the case of tramadol, and lower in the case of celecoxib, than those obtained after administration of reference products alone or in free combination \[[@CR11]\]. In the present study, mean fasting *C*~max~ values after CTC administration were 410 and 244 ng/mL, for celecoxib and tramadol, respectively. This compares with values of 313 and 263 ng/mL in the earlier single-dose Phase 1 study. Similar results were also observed for AUC values \[[@CR11]\]. Differences in values between the two studies are within the range of inter-subject variability. The modified pharmacokinetic profile of tramadol and celecoxib after CTC administration, seen in this earlier study, is consistent with the fasting pharmacokinetic data reported here.

In the present study, the single-dose safety profile of CTC was similar in both fed and fasting conditions. CTC was well tolerated and there were no clinically significant effects of treatment on vital signs, ECGs or physical examination, and no serious AEs, safety-related withdrawals or deaths. The total number of AEs and the number of subjects who experienced at least one AE were similar under both conditions. The most frequently observed AEs were consistent with commonly reported AEs from previous Phase 1 and Phase 2 studies of CTC \[[@CR10]--[@CR12]\] and for standard drug formulations of tramadol and celecoxib \[[@CR13], [@CR14]\].

Conclusion {#Sec14}
==========

In conclusion, food increased the bioavailability of celecoxib from CTC in healthy subjects but had no effect on the bioavailability of tramadol. These findings are in line with those reported for the standard drug formulations of the individual reference products \[[@CR13], [@CR14]\]. The food effect on the bioavailability of celecoxib after CTC administration was not sufficient to indicate that any dose adjustment would be required. In line with dosing recommendations for other tramadol and celecoxib preparations \[[@CR14], [@CR19]\], it is anticipated that no specific dosing recommendations will be necessary in relation to meal times. Following demonstration of efficacy in a Phase 2 study of acute pain following an oral surgical procedure \[[@CR10]\], CTC is now under evaluation in Phase 3 studies of bunionectomy with osteotomy \[[@CR20]\], acute pain following an oral surgical procedure \[[@CR21]\] and hysterectomy-related pain \[[@CR22]\].
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=================================

 {#Sec15}

Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 48 kb)

We thank all study participants and study staff. The study was funded by Esteve Pharmaceuticals, S.A. and was carried out by Algorithme Pharma. Bioanalytical analyses were conducted by Esteve Pharmaceuticals, S.A. Pharmacokinetic analyses were conducted by Algorithme Pharma. Medical writing support was provided by Hannah Mace, MPharmacol at Aspire Scientific (Bollington, UK), and was funded by Mundipharma Research GmbH & Co.KG (Limburg, Germany). CTC is in development by Mundipharma Research and Esteve Pharmaceuticals, S.A., as MR308 and E-58425.

GE and SV were involved in the conception and design of the study and the interpretation of data. NG and CP-S were involved in the conception and design of the study. KS was involved in the interpretation of data. MEn, MEs, ML and ES were involved in the acquisition, analysis, and interpretation of data. All authors reviewed drafts of the manuscript, approved the final version and agree to be accountable for the work.

Conflict of interest {#FPar2}
====================

GE, MEn, MEs, NG and CP-S are employees of Esteve Pharmaceuticals, S.A. SV was an employee of Esteve Pharmaceuticals, S.A. at the time of the clinical trial. KS is an employee of Mundipharma Research Ltd. ES and ML have no potential conflict of interest to declare.

Ethical approval {#FPar3}
================

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent {#FPar4}
================

Informed consent was obtained from all individual participants included in the study.
